The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies
Open accessAbstract
Neurodegeneration, a result of multiple dysregulatory events, is a lengthy multistep process manifested by accrual of mutant variants and abnormal expression, posttranslational modification, and processing of certain proteins. Accumulation of these dysregulated processes requires a mechanism that maintains their functional stability and allows the evolution of the neurodegenerative phenotype. In malignant cells, the capacity to buffer transformation has been attributed to heat-shock protein 90 (Hsp90). Although normal proteins seem to require limited assistance from the chaperone, their aberrant counterparts seem to be highly dependent on Hsp90. Whereas enhanced Hsp90 affinity for mutated or functionally deregulated client proteins has been observed for several oncoproteins, it is unknown whether Hsp90 plays a similar role for neuronal proteins and thus maintains and facilitates the transformed phenotype in neurodegenerative diseases. Tauopathies are neurodegenerative diseases characterized by aberrant phosphorylation and/or expression of Tau protein, leading to a time-dependent accumulation of Tau aggregates and subsequent neuronal death. Here, we show that the stability of p35, a neuronal protein that activates cyclin-dependent protein kinase 5 through complex formation leading to aberrant Tau phosphorylation, and that of mutant but not WT Tau protein is maintained in tauopathies by Hsp90. Inhibition of Hsp90 in cellular and mouse models of tauopathies leads to a reduction of the pathogenic activity of these proteins and results in elimination of aggregated Tau. The results identify important roles played by Hsp90 in maintaining and facilitating the degenerative phenotype in these diseases and provide a common principle governing cancer and neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371
Zou, J., Guo, Y., Guettouche, T., Smith, D. F., & Voellmy, R. (1998) · Cell · doi:10.1016/s0092-8674(00)81588-3 · Cited by 1,232
p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5
Tsai, L.-H., Delalle, I., Caviness, V. S., Chae, T., & Harlow, E. (1994) · Nature · doi:10.1038/371419a0 · Cited by 922
Greenberg, S. G., & Davies, P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.15.5827 · Cited by 730
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms
Andorfer, C., Kress, Y., Espinoza, M., De Silva, R., Tucker, K. L., Barde, Y., Duff, K., & Davies, P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01879.x · Cited by 722
Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides
Xu, H., Gouras, G. K., Greenfield, J. P., Vincent, B., Naslund, J., Mazzarelli, L., Fried, G., Jovanovic, J. N., Seeger, M., Relkin, N. R., et al. (1998) · Nature Medicine · doi:10.1038/nm0498-447 · Cited by 560
Self-citationAbnormal Alzheimer‐like phosphorylation of tau‐protein by cyclin‐dependent kinases cdk2 and cdk5
Baumann, K., Mandelkow, E.-M., Biernat, J., Piwnica-Worms, H., & Mandelkow, E. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80849-p · Cited by 478
Mimnaugh, E. G., Chavany, C., & Neckers, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.37.22796 · Cited by 466
Chaperones increase association of tau protein with microtubules
Dou, F., Netzer, W. J., Tanemura, K., Li, F., Hartl, F. U., Takashima, A., Gouras, G. K., Greengard, P., & Xu, H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242720499 · Cited by 461
Self-citationSittler, A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1307 · Cited by 442
Mutations causing neurodegenerative tauopathies
Goedert, M., & Jakes, R. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.08.007 · Cited by 438
An Isoform of the Neuronal Cyclin-dependent Kinase 5 (Cdk5) Activator
Tang, D., Yeung, J., Lee, K.-Y., Matsushita, M., Matsui, H., Tomizawa, K., Hatase, O., & Wang, J. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.26897 · Cited by 340
Pharmacological prevention of Parkinson disease in Drosophila
Auluck, P. K., & Bonini, N. M. (2002) · Nature Medicine · doi:10.1038/nm1102-1185 · Cited by 280
Polypeptide release by Hsp90 involves ATP hydrolysis and is enhanced by the co-chaperone p23
Young, J. C. (2000) · The EMBO Journal · doi:10.1093/emboj/19.21.5930 · Cited by 232
Fetal‐Type Phosphorylation of the τ in Paired Helical Filaments
Kanemaru, K., Takio, K., Miura, R., Titani, K., & Ihara, Y. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb10039.x · Cited by 219
In vivo evidence of CHIP up‐regulation attenuating tau aggregation
Sahara, N., Murayama, M., Mizoroki, T., Urushitani, M., Imai, Y., Takahashi, R., Murata, S., Tanaka, K., & Takashima, A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03272.x · Cited by 209
A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains
Tseng, H.-C., Zhou, Y., Shen, Y., & Tsai, L.-H. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02934-4 · Cited by 198
Paglini, G., Pigino, G., Kunda, P., Morfini, G., Maccioni, R., Quiroga, S., Ferreira, A., & Cáceres, A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-23-09858.1998 · Cited by 191
A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons
Zheng, Y., Kesavapany, S., Gravell, M., Hamilton, R. S., Schubert, M., Amin, N., Albers, W., Grant, P., & Pant, H. C. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600441 · Cited by 189
Identification of Potent Water Soluble Purine-Scaffold Inhibitors of the Heat Shock Protein 90
He, H., Zatorska, D., Kim, J., Aguirre, J., Llauger, L., She, Y., Wu, N., Immormino, R. M., Gewirth, D. T., & Chiosis, G. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0508078 · Cited by 177
Self-citationRole of Serine/Threonine Protein Phosphatase in Alzheimer’s Disease
Tian, Q., & Wang, J. (2002) · Neurosignals · doi:10.1159/000067425 · Cited by 172
Targeting Wide-Range Oncogenic Transformation via PU24FCl, a Specific Inhibitor of Tumor Hsp90
Vilenchik, M., Solit, D., Basso, A., Huezo, H., Lucas, B., He, H., Rosen, N., Spampinato, C., Modrich, P., & Chiosis, G. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.04.008 · Cited by 171
Self-citationDifferential expression of protein phosphatase 1 isoforms in mammalian brain
da Cruz e Silva, E., Fox, C., Ouimet, C., Gustafson, E., Watson, S., & Greengard, P. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-05-03375.1995 · Cited by 163
Self-citationSahara, N., Lewis, J. M., Deture, M. A., McGowan, E. M., Dickson, D. W., Hutton, M., & Yen, S.-H. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01241.x · Cited by 134
Phosphorylated tau and the neurodegenerative foldopathies
Kosik, K. S., & Shimura, H. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.10.011 · Cited by 130
Regulation of cyclin-dependent kinase 5 and casein kinase 1 by metabotropic glutamate receptors
Liu, F., Ma, X.-H., Ule, J., Bibb, J. A., Nishi, A., DeMaggio, A. J., Yan, Z., Nairn, A. C., & Greengard, P. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191353898 · Cited by 127
Self-citationZhang, M., Li, J., Chakrabarty, P., Bu, B., & Vincent, I. J. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63347-0 · Cited by 110
Ishiguro, K., Omori, A., Sato, K., Tomizawa, K., Imahori, K., & Uchida, T. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90259-v · Cited by 109
Heat-shock protein 90 and Cdc37 interact with LKB1 and regulate its stability
Boudeau, J., Deák, M., Lawlor, M. A., MORRICE, N. A., & Alessi, D. R. (2003) · Biochemical Journal · doi:10.1042/bj20021813 · Cited by 98
Singh, T. J., Zaidi, T., Grundke, I., & Iqbal, K. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01383-c · Cited by 93
Michel, G., Mercken, M., Murayama, M., Noguchi, K., Ishiguro, K., Imahori, K., & Takashima, A. (1998) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(97)00139-6 · Cited by 92
Interaction between Cdc37 and Cdk4 in human cells
Lamphere, L., Fiore, F., Xu, X., Brizuela, L., Keezer, S. M., Sardet, C., Draetta, G. F., & Gyuris, J. (1997) · Oncogene · doi:10.1038/sj.onc.1201036 · Cited by 92
Zheng, Y., Li, B., Amin, N. D., Albers, W., & Pant, H. C. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.03133.x · Cited by 91
Chaperoning Oncogenes: Hsp90 as a Target of Geldanamycin
Neckers, L. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-29717-0_11 · Cited by 85
Takahashi, S., Ohshima, T., Cho, A., Sreenath, T., Iadarola, M. J., Pant, H. C., Kim, Y. D., Nairn, A. C., Brady, R. O., Greengard, P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409456102 · Cited by 80
Self-citationTargeting chaperones in transformed systems – a focus on Hsp90 and cancer
Chiosis, G. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.1.37 · Cited by 80
Self-citationHeat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
Chiosis, G., Lopes, E. C., & Solit, D. B. (2006) · PubMed · Cited by 79
Self-citationInhibitors of the HSP90 Molecular Chaperone: Attacking the Master Regulator in Cancer
McDonald, E., Workman, P., & Jones, K. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777812004 · Cited by 75
Tau Protein Phosphorylation as a Therapeutic Target in Alzheimers Disease
Lau, L., Schachter, J. B., Seymour, P. A., & Sanner, M. A. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026024607526 · Cited by 62
Tau is central in the genetic Alzheimer–frontotemporal dementia spectrum
Dermaut, B., Kumar‐Singh, S., Rademakers, R., Theuns, J., Cruts, M., & Broeckhoven, C. V. (2005) · Trends in Genetics · doi:10.1016/j.tig.2005.09.005 · Cited by 60
Functional Interactions of Tau and their Relevance for Alzheimers Disease
Brandt, R., & Leschik, J. (2004) · Current Alzheimer Research · doi:10.2174/1567205043332054 · Cited by 45
Rademakers, R., Sleegers, K., Theuns, J., den Broeck, M. V., Kacem, S. B., Nilsson, L., Adolfsson, R., van Duijn, C. M., Broeckhoven, C. V., & Cruts, M. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.10.003 · Cited by 35
Clinicopathological features of the tauopathies
Murray, B., Lynch, T., & Farrell, M. (2005) · Biochemical Society Transactions · doi:10.1042/bst0330595 · Cited by 29
Cited by
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Roles of tau protein in health and disease
Guo, T., Noble, W., & Hanger, D. P. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1707-9 · Cited by 1,003
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Alzheimer's Disease: From Pathology to Therapeutic Approaches
Jakob‐Roetne, R., & Jacobsen, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802808 · Cited by 626
Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing
Wang, Y., Martinez-Vicente, M., Krüger, U., Kaushik, S., Wong, E., Mandelkow, E.-M., Cuervo, A. M., & Mandelkow, E. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp367 · Cited by 617
Metadata
- Authors
- Luo, W., Dou, F., Rodina, A., Chip, S., Kim, J., Zhao, Q., Moulick, K., Aguirre, J., Wu, N., Greengard, P., & Chiosis, G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2007-05-29
- Volume
- 104
- Issue
- 22
- Pages
- 9511-9516
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2058519323
- Cited by
- 274
- References
- 46
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.